S.Korea's pharma firms plunge after SillaJen's halted clinical tests

SillaJen

05/08/2019 05:32

** South Korea's pharmaceutical stocks stumble as sentiment
across the sector dampens after SillaJen  215600.KQ  was advised
to suspend clinical tests
    ** SillaJen says http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20190802900043
 Independent Data Monitoring Committee (DMC) has advised to halt
company's clinical tests for liver cancer treatment Pexa-Vec
    ** Company will report DMC's recommendation to U.S. Food and
Drug Administration - regulatory filing
    ** Shares of Celltrion  068270.KS  and Samsung BioLogics
 207940.KS  drop 8.9% and 7%, respectively, pushing the medical
sub-index  .KS32  down more than 6%
    ** SillaJen shares decline nearly 30%, after losing 30% in
the previous session
    ** The broader KOSPI market  .KS11  was trading down more
than 2%, while the junior KOSDAQ market  .KQ11  was trading down
4.7%

 ((hayoung.choi.thomsonreuters.com@reuters.net))